Autonomix medical, inc. announces closing of $10.0 million underwritten public offering including partial exercise of over-allotment option

The woodlands, tx, nov. 25, 2024 (globe newswire) -- autonomix medical, inc. (nasdaq: amix) (“autonomix” or the “company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced the closing of its previously announced underwritten public offering of common stock units and pre-funded warrant units for aggregate gross proceeds of approximately $10.0 million, prior to deducting underwriting discounts and commissions and offering expenses, which amount includes the partial exercise of the over-allotment option granted to the underwriter.
AMIX Ratings Summary
AMIX Quant Ranking